We are developing multiple clinical strategies to target neoantigens, including NEON / ONE product candidates focused on personal neoantigen vaccines and personal autologous T cell therapies, and NEON / SELECT product candidates focused on neoantigen targets that are shared across patient populations.

RESEARCH & PRECLINICAL DEVELOPMENT
PHASE 1
LATER STAGE DEVELOPMENT

NEO-PV-01

Personal neoantigen vaccine
NT-001: αPD-1 (Opdivo®) Combo – Melanoma, NSCLC, Bladder Cancer
NT-002: αPD-1 (Keytruda®) + Chemo Combo – NSCLC
NT-003: αPD-1 + aCD40 / αCTLA4 Combo – Melanoma
NT-004: Trial in earlier disease setting

NEO-PTC-01

Personal neoantigen T cell therapy
Phase 1 Trial in solid tumor setting
TARGET
DISCOVERY
TARGET
VALIDATION
PRECLINICAL
DEVELOPMENT
PHASE 1
LATER STAGE DEVELOPMENT

NEO-SV-01

Breast neoantigen vaccine
Phase 1 Trial in breast cancer